Vericel Capital Stock vs Current Deferred Revenue Analysis
VCEL Stock | USD 59.11 2.40 4.23% |
Vericel Corp financial indicator trend analysis is much more than just breaking down Vericel Corp Ord prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Vericel Corp Ord is a good investment. Please check the relationship between Vericel Corp Capital Stock and its Current Deferred Revenue accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Vericel Corp Ord. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income.
Capital Stock vs Current Deferred Revenue
Capital Stock vs Current Deferred Revenue Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Vericel Corp Ord Capital Stock account and Current Deferred Revenue. At this time, the significance of the direction appears to have very week relationship.
The correlation between Vericel Corp's Capital Stock and Current Deferred Revenue is 0.2. Overlapping area represents the amount of variation of Capital Stock that can explain the historical movement of Current Deferred Revenue in the same time period over historical financial statements of Vericel Corp Ord, assuming nothing else is changed. The correlation between historical values of Vericel Corp's Capital Stock and Current Deferred Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Capital Stock of Vericel Corp Ord are associated (or correlated) with its Current Deferred Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Current Deferred Revenue has no effect on the direction of Capital Stock i.e., Vericel Corp's Capital Stock and Current Deferred Revenue go up and down completely randomly.
Correlation Coefficient | 0.2 |
Relationship Direction | Positive |
Relationship Strength | Very Weak |
Capital Stock
The total amount of a company's capital funded by shareholders through the issue and subscription of shares.Current Deferred Revenue
Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.Most indicators from Vericel Corp's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Vericel Corp Ord current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Vericel Corp Ord. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. At this time, Vericel Corp's Selling General Administrative is quite stable compared to the past year. Enterprise Value Over EBITDA is expected to rise to 621.77 this year, although the value of Issuance Of Capital Stock will most likely fall to about 5 M.
2021 | 2022 | 2023 | 2024 (projected) | Total Operating Expenses | 113.9M | 126.8M | 142.0M | 149.1M | Cost Of Revenue | 50.2M | 54.6M | 61.9M | 65.0M |
Vericel Corp fundamental ratios Correlations
Click cells to compare fundamentals
Vericel Corp Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Vericel Corp fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 153.2M | 205.6M | 243.7M | 273.0M | 353.7M | 371.3M | |
Other Current Liab | 41K | 11.3M | 14.0M | 16.2M | 7.9M | 8.3M | |
Total Current Liabilities | 19.8M | 22.5M | 26.1M | 37.5M | 45.7M | 48.0M | |
Total Stockholder Equity | 111.1M | 134.3M | 170.5M | 192.3M | 226.0M | 237.2M | |
Property Plant And Equipment Net | 32.2M | 57.7M | 59.0M | 57.4M | 115.1M | 120.9M | |
Net Debt | 814K | 19.6M | (18.2M) | (3.5M) | 19.0M | 19.9M | |
Retained Earnings | (378.7M) | (375.8M) | (383.3M) | (400.0M) | (403.2M) | (383.0M) | |
Accounts Payable | 6.3M | 6.8M | 9.0M | 16.9M | 22.3M | 23.5M | |
Cash | 26.9M | 33.6M | 68.3M | 51.1M | 86.9M | 91.2M | |
Non Current Assets Total | 41.6M | 82.0M | 85.2M | 86.1M | 148.0M | 155.4M | |
Cash And Short Term Investments | 69.7M | 75.8M | 103.4M | 119.5M | 109.6M | 115.0M | |
Net Receivables | 32.2M | 34.5M | 37.4M | 46.5M | 58.4M | 61.3M | |
Common Stock Shares Outstanding | 44.2M | 47.3M | 46.5M | 47.1M | 47.6M | 50.0M | |
Liabilities And Stockholders Equity | 153.2M | 205.6M | 243.7M | 273.0M | 353.7M | 371.3M | |
Non Current Liabilities Total | 22.4M | 48.9M | 47.2M | 43.3M | 82.0M | 86.1M | |
Other Current Assets | 3.0M | 3.9M | 4.2M | 4.8M | 24.6M | 25.9M | |
Other Stockholder Equity | 21K | 127.6M | 177.9M | 592.3M | 681.1M | 715.2M | |
Total Liab | 42.1M | 71.3M | 73.2M | 80.7M | 127.7M | 134.1M | |
Property Plant And Equipment Gross | 32.2M | 30K | 59.0M | 57.4M | 137.3M | 144.2M | |
Total Current Assets | 111.7M | 123.6M | 158.5M | 186.9M | 205.6M | 215.9M | |
Accumulated Other Comprehensive Income | 21K | 14K | (154K) | (978K) | (100K) | (105K) | |
Common Stock Total Equity | 489.7M | 6.6M | 553.9M | 593.2M | 682.2M | 716.3M | |
Short Term Investments | 42.8M | 42.2M | 35.1M | 68.5M | 40.5M | 42.5M | |
Common Stock | 489.7M | 510.1M | 553.9M | 593.2M | 629.2M | 660.7M | |
Inventory | 6.8M | 9.4M | 13.4M | 16.0M | 13.1M | 13.7M | |
Property Plant Equipment | 32.2M | 57.7M | 59.0M | 57.4M | 66.0M | 69.3M | |
Net Tangible Assets | 111.1M | 134.3M | 170.5M | 184.8M | 212.5M | 223.1M | |
Retained Earnings Total Equity | (378.7M) | (375.8M) | (383.3M) | (400.0M) | (360.0M) | (378.0M) | |
Non Currrent Assets Other | 89K | 211K | 528K | 1.3M | 771K | 732.5K |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out World Market Map to better understand how to build diversified portfolios, which includes a position in Vericel Corp Ord. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Vericel Corp. If investors know Vericel will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Vericel Corp listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 1.045 | Earnings Share 0.08 | Revenue Per Share 4.685 | Quarterly Revenue Growth 0.27 | Return On Assets (0) |
The market value of Vericel Corp Ord is measured differently than its book value, which is the value of Vericel that is recorded on the company's balance sheet. Investors also form their own opinion of Vericel Corp's value that differs from its market value or its book value, called intrinsic value, which is Vericel Corp's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Vericel Corp's market value can be influenced by many factors that don't directly affect Vericel Corp's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Vericel Corp's value and its price as these two are different measures arrived at by different means. Investors typically determine if Vericel Corp is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Vericel Corp's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.